BCG immunotherapy is the gold-standard treatment for non-muscle-invasive bladder cancer
at high risk of recurrence or progression. Preclinical and clinical studies have revealed that a …

Abstract Bacillus Calmette–Guérin (BCG) has been used to treat non-muscle-invasive
bladder cancer for more than 30 years. It is one of the most successful biotherapies for …

PURPOSE: Of all medical disciplines it is exclusively in urology in which immunotherapy for
cancer has an established position today with intravesical bacillus Calmette-Guerin (BCG) …

Bladder cancer is one of the most significant genitourinary cancer, causing high morbidity
and mortality in a great number of patients. Over the years, various treatment methods for …

Simple Summary Tumor-associated macrophages (TAMs) play major roles in solid tumor
development. They can have both anti-tumor and pro-tumor properties depending on their …

Simple Summary Bacillus Calmette–Guérin (BCG), a live attenuated strain of Mycobacterium
bovis, is the most successful microbial immunotherapy of cancer in current use. Intravesical …

Background BCG is recommended as intravesical immunotherapy to reduce the risk of
tumor recurrence in patients with non-muscle invasive bladder cancer (NMIBC). Currently, it …

ABSTRACT The Bacillus Calmette–Guérin (BCG) vaccine is the oldest cancer
immunotherapeutic agent in use. Despite its effectiveness, its initial mechanisms of action …

Abstract Bacillus Calmette-Guerin (BCG) is the only FDA approved first line therapy for
patients with nonmuscle invasive bladder cancer. Since the turn of the 20th century BCG has …

Infiltration by macrophages represents a characteristic morphological hallmark in high-grade
lymphatic malignancies such as Burkitt's lymphoma (BL). Although macrophages can, in …